

Drug Name: Relistor (methylnaltrexone bromide)

Date: 12-2017 **Revised Date:** 7/2018

Drug Name:	Relistor (methylnaltrexone bromide)
Required Medical Information:	 Patient is an adult being treated for documented opioid-induced constipation with advanced illness who is receiving palliative care, and Patient has failed, or has a documented intolerance or contraindication to, polyethylene glycol and one other laxative (e.g., senna, bisacodyl, lactulose) where effectiveness of each therapy option has been evaluated after 1 or 2 weeks; and Patient does not have known or suspected mechanical gastrointestinal obstruction and does not have a catheter in their abdominal wall.
	 Patient is an adult who is currently receiving treatment with an opioid; and Patient has received an opioid for at least 4 weeks; and Patient is currently diagnosed with opioid-induced constipation (OIC) for chronic non-cancer pain; and Patient has less than 3 bowel movements [BMs] per week, excessive straining, incomplete evacuations, hard or lumpy stools; and Patient has failed, or has a documented intolerance or contraindication to, polyethylene glycol and one other laxative (e.g., senna, bisacodyl, lactulose) where effectiveness of each therapy option has been evaluated after 1 or 2 weeks; and Patient has failed, or has a documented intolerance or contraindication to, Movantik; and Patient does not have known or suspected mechanical gastrointestinal obstruction and does not have a catheter in their abdominal wall.
Note(s):	 The patient had a positive documented response to the medication. Advanced illness is defined by one of the following: cancer, heart and blood vessel problems (e.g. cardiovascular disease), lung problems (eg, emphysema
Coverage duration:	or COPD), or Alzheimer's disease. Initial: 3 months Renewals: 6 months